SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Over-pricing charge: Cipla gets new demand notice for Rs 73 cr

29 Dec 2010 Evaluate

Cipla has received two fresh notices from the Government demanding a total of Rs 73 crore for alleged over-pricing on two drugs. The notices, from the National Pharmaceutical Pricing Authority (NPPA), demanded Rs 47.70 crore for respiratory drug Salbutamol and Rs 25.46 crore for antibiotic Ciprofloxacin.

Cipla has been litigating over the NPPA's notices on five of its drugs, including the aforementioned two, for about 10 years now. And the over-charge amount claimed by the Government from Cipla has crossed Rs 1,000 crore. The other drugs from Cipla under the scanner for alleged over-charging include respiratory drug Theophylline, cephalosporin-antibiotic Cefadroxil and antibiotic Norfloxacin.

Cipla Share Price

1228.90 -9.40 (-0.76%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×